دورية أكاديمية
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies.
| العنوان: | The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies. |
|---|---|
| المؤلفون: | Kashani B; Hematology, Oncology and Stem Cell Transplantation Research Center, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.; Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Zandi Z; Hematology, Oncology and Stem Cell Transplantation Research Center, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.; Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Pourbagheri-Sigaroodi A; Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Yousefi AM; Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Ghaffari SH; Hematology, Oncology and Stem Cell Transplantation Research Center, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran., Bashash D; Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. |
| المصدر: | Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jul; Vol. 24 (7), pp. 493-512. Date of Electronic Publication: 2024 May 08. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd., c2001- |
| مواضيع طبية MeSH: | Signal Transduction* , Phosphatidylinositol 3-Kinases*/metabolism , Lymphopoiesis* , Phosphoinositide-3 Kinase Inhibitors*/pharmacology , Phosphoinositide-3 Kinase Inhibitors*/administration & dosage , Lymphoma*/pathology , Lymphoma*/drug therapy , Drug Development*, Humans ; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/administration & dosage ; Disease Progression ; Molecular Targeted Therapy ; Drug Design ; Cell Differentiation |
| مستخلص: | Introduction: As a vital mechanism of survival, lymphopoiesis requires the collaboration of different signaling molecules to orchestrate each step of cell development and maturation. The PI3K pathway is considerably involved in the maturation of lymphatic cells and therefore, its dysregulation can immensely affect human well-being and cause some of the most prevalent malignancies. As a result, studies that investigate this pathway could pave the way for a better understanding of the lymphopoiesis mechanisms, the undesired changes that lead to cancer progression, and how to design drugs to solve this issue. Areas Covered: The present review addresses the aforementioned aspects of the PI3K pathway and helps pave the way for future therapeutic approaches. In order to access the articles, databases such as Medicine Medline/PubMed, Scopus, Google Scholar, and Science Direct were utilized. The search formula was established by identifying main keywords including PI3K/Akt/mTOR pathway, Lymphopoiesis, Lymphoid malignancies, and inhibitors. Expert Opinion: The PI3K pathway is crucial for lymphocyte development and differentiation, making it a potential target for therapeutic intervention in lymphoid cancers. Studies are focused on developing PI3K inhibitors to impede the progression of hematologic malignancies, highlighting the pathway's significance in lymphoma and lymphoid leukemia. |
| فهرسة مساهمة: | Keywords: B cell; NK cell; PI3K pathway; T cell; lymphoid malignancies; lymphopoiesis |
| المشرفين على المادة: | EC 2.7.1.- (Phosphatidylinositol 3-Kinases) 0 (Phosphoinositide-3 Kinase Inhibitors) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240501 Date Completed: 20240620 Latest Revision: 20240620 |
| رمز التحديث: | 20240620 |
| DOI: | 10.1080/14737140.2024.2350629 |
| PMID: | 38690706 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8328 |
|---|---|
| DOI: | 10.1080/14737140.2024.2350629 |